Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 9, 2018 | Series C | $52M | 1 | — | — | Detail |
May 2, 2017 | Series B | $50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Be The Match BioTherapies | — | Series C |